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Abstract 
The synthesis and characterization of an oxidovanadium(IV) [VIVO(L)(acac)] (1) and of two dioxidovanadium(V) 
[VVO2(L')] (2) and [VVO2(L)] (2a) complexes of the Schiff base formed from the reaction of 4-(p-fluorophenyl) 
thiosemicarbazone with pyridine-2-aldehyde (HL) is described. The oxidovanadium(IV) species [VIVO(L)(acac)] (1) 
was synthesized by the reaction of VIVO(acac)2 with the thiosemicarbazone HL in refluxing ethanol. The 
recrystallization of [VIVO(L)(acac)] (1) in DMF, CH3CN or EtOH gave the same product i.e. the dioxidovanadium(V) 
complex [VVO2(L)] (2a); however, upon recrystallization of 1 in DMSO  a distinct compound [VVO2(L')] (2) was 
formed, wherein the original ligand L  is transformed to a rearranged one, L’. In the presence of DMSO the ligand 
in complex 1 is found to undergo methylation at the carbon centre attached to imine nitrogen (aldimine) and 
transformed to the corresponding VVO2- species through in situ reaction. The synthesized HL and the metal 
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complexes were characterized by elemental analysis, IR, UV–Vis, NMR and EPR spectroscopy. The molecular 
structure of [VVO2(L')] (2) was determined by single crystal X–ray crystallography. The methylation of various other 
ligands and complexes prepared from different vanadium precursors under similar reaction conditions was also 
attempted and it was confirmed that the imine methylation observed is both ligand and metal precursor specific. 
Complexes 1 and 2 show in vitro insulin-like activity against insulin responsive L6 myoblast cells, with complex 1 
being more potent. In addition, the in vitro cytotoxicity studies of HL, and of complexes 1 and 2 against the MCF–7 
and Vero cell lines were also done. The ligand is not cytotoxic and complex 2 is significantly more cytotoxic than 1. 
DAPI staining experiments indicate that increase in time of incubation as well as increase of concentration of the 
complexes lead to increase in cell death. 
_____________________________________________________________________________________ 
 
 
Introduction 
Reports of dimethylsulfoxide (DMSO) acting as a methylating agent in aromatic hydrocarbons1a and in N-
methylation of amines1b,c have attracted significant attention, but DMSO is a comparatively stable molecule and 
has very few applications as reactant in organic reactions.1d The methylation of the C5 carbon of deoxycytosine 
nucleotide was reported to be brought about by DMSO in the presence of Fenton’s reagent, where a methyl 
radical generated from DMSO is responsible for the methylation.1e Another example is the methylation of aromatic 
hydrocarbons by DMSO reported to take place via the methylsulfinyl carbanion generated from DMSO. 1a DMSO 
was also reported to be a methylating agent for amines under catalyst free conditions.1b  
The coordination chemistry of vanadium has attracted increasing interest, due to its biological properties, 2–9 and 
for the use of oxidovanadium complexes in oxidation and oxo transfer reactions catalysis,10-16 and potential 
medicinal applications.17-21 Vanadium is one of the trace bio-elements existing in the human body whose 
complexes have been found to show antibacterial, antitumor, insulin-enhancing and anti-parasitic effects. 17,19–
21a,22-25,26 Vanadium complexes could also suppress the growth and spread of existing tumours by inhibiting tumour 
cell proliferation, inducing apoptosis and limiting the invasion and metastatic potential of neoplastic cells. 19,20,25,27–
28 Inorganic VIVO- and VVO2-compounds, as well as some vanadium(IV)/(V) compounds, are insulin-enhancing 
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agents 17,19,29-33 and the discovery of the in vivo insulin mimesis per os of oxidovanadates(V),34 of the 
oxidovanadium(IV)- (VIVO-) precursor, VIVOSO4,35 and of the more potent bis(maltolato)-oxidovanadium(IV) (BMOV) 
30,32,36,37 encouraged exploration of vanadium complexes for the treatment of type II diabetes, as well as many 
attempts to understand the mechanisms of action. 30,32,37-41 Thus several different approaches have been used to 
develop orally active vanadium containing insulin enhancing agents.32,33,41,42,43  
Thiosemicarbazones are an important class of compounds that have considerable pharmacological interest due to 
their antibacterial, anti-viral, anti-malarial, anti-leprotic, anti-tumor and anti-cancer activities.44–47 Metal complexes 
of thiosemicarbazone ligands have shown variable bonding properties and structural diversity, along with 
promising biological applications and ion sensing abilities.48–59  
Keeping these factors in mind and in applying our expertise in oxidovanadium chemistry, 60 herein we report the 
formation of an oxidovanadium(IV) complex [VIVO(L)(acac)] (1) derived from the Schiff base formed by the 
condensation of 4-(p-fluorophenyl)thiosemicarbazone with pyridine-2-aldehyde (HL), which gradually oxidizes to 
the dioxidovanadium(V) complex [VVO2(L')] (2) upon standing in DMSO solution, with an unprecedented 
methylation of the aldimine carbon in the ligand backbone (Scheme 1). No such methylation occurs upon 
recrystallization of 1 in other solvents such as DMF, CH3CN, EtOH, where [VIVO(L)(acac)] (1) undergoes oxidation to 
[VVO2(L)] (2a), with no modification in the ligand backbone.  
The synthesized ligand and the metal complexes were characterized by elemental analysis, IR, UV–Vis, NMR and 
EPR spectroscopy. The molecular structure of [VVO2(L')] (2) was also determined by single crystal X–ray diffraction 
crystallography (XRD). The outline of the process of formation of the methylated oxidovanadium(V) complex 2 is 
tentatively explained and further supported by DFT calculations. In addition, from the comparative study of various 
other ligands and complexes prepared from different vanadium precursors in similar reaction conditions, it has 
been fortified that the imine methylation observed is both ligand and metal precursor specific for this system.  
Complexes 1 and 2 were assayed for their in vitro insulin-like activity against insulin responsive L6 myoblast cells. 
Results indicate both complex 1 and 2 to exhibit considerable insulin-like activity, with 1 being more potent than 2. 
In addition, the in vitro toxicity studies of complexes 1 and 2 against MCF–7 (breast cancer cells) and Vero cells 
(noncancerous mammalian cells) were also assayed and complex 1 was found to have higher cytotoxicity towards 
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the cell lines. Results of DAPI staining experiments carried out indicated that increase in time of incubation and/or 
increase of concentration of complexes 1 and 2 lead to increase in cell death.  
Experimental Section 
Materials and methods 
[VIVO(acac)2], where acac is acetylacetonate, was prepared as described in the literature.61 Reagent grade solvents were dried 
and distilled prior to use. All other chemicals were of reagent grade, available commercially and used as received. HPLC grade 
DMSO and CH3CN were used for spectroscopic and electrochemical studies, and ethanol or methanol were used for synthesis of 
ligands and metal complexes. Commercially available TEAP (tetraethylammonium perchlorate) was properly dried and used as a 
supporting electrolyte for recording cyclic voltammograms of the complexes. Elemental analyses were made on a Vario ELcube 
CHNS Elemental analyzer. IR spectra were recorded on a Perkin-Elmer Spectrum RXI spectrometer. 1H and 13C NMR spectra 
were recorded with a Bruker Ultrashield 400 MHz spectrometer using SiMe4 as an internal standard and 51V NMR spectra were 
obtained on a Bruker Avance III 400 MHz spectrometer and chemical shift 51V values (δV) were referenced relative to neat 
VVOCl3 as external standard. Electronic spectra were recorded on a Lamda 25, PerkinElmer spectrophotometer. Electrochemical 
data were collected using PAR Versastat-II instrument driven by E-chem software (PAR) at 298 K in a dry nitrogen atmosphere. 
Cyclic voltammetry experiments were carried out with Pt working and auxiliary electrodes and Ag/AgCl as reference electrode. 
EPR spectra were recorded with a Bruker EMX X-band spectrometer either at 77 K or at room temperature. X-band EPR 
measurements were carried out on a JEOL JES-FA 200 and Bruker EMX EPR Spectrometer. The mass spectrometer used is an ion 
trap equipped with an ESI ion source (Thermo Scientific). The mass spectrometer was operated in the ESI positive and negative 
ion modes, with the following optimized parameters: ion spray voltage, + 4/ -5.3 kV; capillary voltage, 5/-20 V; tube lens offset, 
63/-124; sheath gas (N2), 20 arbitrary units; capillary temperature 275 ºC. The spectra, typically correspond to the average of 
20-30 scans, and were recorded in the range 100-2000 Da. MCF–7 cells (a human breast adenocarcinoma cell line) and Vero 
cells (noncancerous mammalian cells, to check the effect of the complexes on the noncancerous cells) were obtained from the 
National Centre of Cell Science (NCCS), Pune, India and were maintained in minimal essential medium supplemented with 10% 
fetal bovine serum (FBS), penicillin-streptomycin solution and incubated at 37°C in 5% CO2 and 95% humidified incubator.  
Synthesis of ligand (HL) 
The thiosemicabazide was prepared from distilled p-fluoroaniline by a method reported earlier.62  The Schiff base ligand, 4-(p-
fluorophenyl) thiosemicarbazone of pyridine-2-aldehyde, was prepared in 80–90% yield by stirring an equimolar ratio of the 
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thiosemicabazide with pyridine-2-aldehyde in methanol medium by standard procedures.63 The resulting compound was 
filtered, washed thoroughly with methanol and dried over fused CaCl2.  
HL: Yield: 85%. Anal. calc. for C13H11N4SF: C, 56.92; H, 4.04; N, 20.42. Found: C, 56.95; H, 4.00; N, 20.41. Main IR peaks (KBr, 
cm1): ν(N(1)–H), 3311 s; ν(N(2)–H), 2967 s; ν(C(8)–H), 2825 m; ν(C=C), 1638 s; ν(C(7)–S(1)), 836 s. 1H NMR (DMSO–d6, 400 MHz, 
ppm): δH: 12.08 (s, 1H, N(1)H), 10.29 (s, 1H, N(2)H), 8.59 (s, 1H, C(8)H), 8.58–7.20 (m, 8H, C6H4). 13C NMR (DMSO-d6, 100 MHz, 
ppm): δc: 177.25, 161.46, 159.05, 153.58, 149.82, 143.62, 136.98, 135.77, 128.86, 128.77, 124.76, 121.12, 115.37. 
Synthesis of [VIVO(L)(acac)] (1)  
 To a solution of HL (0.274 g, 0.100 mmol) in hot ethanol, VIVO(acac)2 (0.265 g, 1.0 mmol) was added. The mixture was refluxed 
for 2 h, yielding a dark green color crystalline precipitate of [VIVO(L)(acac)] (1): Yield: 75%. Anal. calc. for C18H17FN4VO3S: C, 
49.21; H, 3.90; N, 12.75. Found: C, 49.24; H, 3.87; N, 12.73. Main solid state IR peaks (KBr, cm1): ν(N(1)–H), 3317 s; ν(C=C), 1602 
s; ν(V=O), 949 s; ν(C(7)–S(1)), 762 s. Spin Hamiltonian parameters determined from EPR spectra at 77 K: gx,y =1.978, gz=1.952, 
|Ax,y| = 51.9×104 cm1, |Az| = 153.2×104 cm1. 
Synthesis of [VVO2(L´)] (2) 
The dark green crystalline [VIVO(L)(acac)] (1) was dissolved in DMSO at 60⁰C and allowed to evaporate at room temperature for 
recrystallization. Reddish brown crystals were obtained from DMSO after 15 days.  
[VVO2(L´)] (2): Yield: 65%. Anal. calc. for C14H12FN4VO2S: C, 45.41; H, 3.27; N, 15.13. Found: C, 45.43; H, 3.25; N, 15.16. Main IR 
peaks (KBr, cm1): ν(N(1)–H), 3268 s; ν(C=C), 1604 s; ν(V=O), 937, 925 s; ν(C(7)–S(1)), 765 s. 1H NMR (DMSO–d6, 400 MHz, ppm): 
δH: 10.20 (s, 1H, N(1)H), 8.72–7.18 (m, 8H, C6H4), 2.66 (s, 3H, C(8)H3). 13C NMR (DMSO-d6, 100 MHz, ppm): δc: 154.34, 153.80, 
143.72, 141.34, 137.23, 130.68, 129.12, 126.94, 125.35, 122.48, 122.40, 115.88, 115.65, 67.87. 51V NMR (DMSO–d6, ppm) δv: -
434, -577. 
Synthesis of [VVO2(L)] (2a) 
The dark green crystalline residue of [VIVO(L)(acac)] (1) was dissolved in EtOH for recrystallization and allowed to evaporate at 
room temperature. A yellow residue of the complex was obtained after few days. Similar results were obtained when 
recrystallization of 1 was done in CH3CN and DMF. 
[VVO2(L)] (2a): Yield: 70%. Anal. calc. for C13H10FN4VO2S: C, 43.83; H, 2.83; N, 15.73. Found: C, 43.80; H, 2.85; N, 15.76. Main IR 
peaks (KBr, cm1): ν(N(1)–H), 3256 s; ν(C(8)–H), 2834 m; ν(C=C), 1589 s; ν(V=O), 934, 922 s; ν(C(7)–S(1)), 775 s. 1H NMR (DMSO–
d6, 400 MHz, ppm): δH 10.29 (s, 1H, N(1)H), 8.79 (s, 1H, C(8)H), 8.78–7.16 (m, 8H, C6H4). 13C NMR (DMSO-d6, 100 MHz, ppm): δc 
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166.16, 160.28, 159.10, 156.73, 150.24, 149.31, 138.11, 137.27, 125.45, 119.96, 119.88, 116.29, 116.06. 51V NMR (DMSO–d6, 
ppm) δv: -434. 
[N-(4-fluorophenyl)-5-(pyridin-2-yl)-1,3,4-thiadiazol-2-amine] (3) 
The compound [VVO2(L)] (2a) was dissolved in DMSO (ca. 25 mM) and the solution kept at 60 ºC. There was no change in colour 
but there was a significant alteration to the 1H NMR spectrum after 5 days under these conditions (Fig. S1). After cooling the 
reaction mixture and letting it stand at room temperature, a crystalline material slowly formed after approximately a week. The 
obtained crystalline product corresponds to a cyclized and oxidized compound 3, which was characterized by single-crystal x-
ray diffraction.   
 
Computational Details 
The full geometry optimization of the molecular structures was carried out at the DFT level of theory using B3P86 functional64 
with the help of the Gaussian-09 program package.65 This functional was found to be sufficiently accurate for the theoretical 
studies of structural parameters and 51V NMR chemical shifts of various V complexes.66 No symmetry operations were applied 
for any of the structures calculated. The geometry optimization was carried out using a relativistic Stuttgart pseudopotential 
which describes 10 core electrons and the appropriate contracted basis set (8s7p6d1f)/[6s5p3d1f] for the vanadium atom67 and 
the 6-31G* basis set for other atoms. The Hessian matrix was calculated analytically for the optimized structures to prove the 
location of correct minima (no imaginary frequencies) and to estimate the thermodynamic parameters, the latter being 
calculated at 25 °C. 
The total energies corrected for solvent effects Es were estimated at the single-point calculations on the basis of gas-
phase geometries at the IEFPCM-B3P86/6-311+G*//gas-B3P86/6-31G* level of theory using the polarizable continuum model in 
the IEFPCM version68 with DMSO as the solvent. The UAKS model was applied for the molecular cavity with dispersion, 
repulsion and cavitation contributions. The entropic term in DMSO solution (Ss) was calculated according to the procedure 
described by Wertz69a and Cooper and Ziegler69b using eqn (1)–(4): 
gasm,liqm,
s
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
         (3) 
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Ss = Sg + Ssol = Sg + [S1 + (Sg + S1) + S2] = 
Sg + [(–11.60 cal/mol·K) – 0.27(Sg – 11.60 cal/mol·K) + 5.25 cal/mol·K]             (4) 
where Sg is the gas-phase entropy of the solute, ΔSsol is the solvation entropy, S°,sliq, S°,sgas and Vsm,liq are the standard entropies 
and molar volumes of the solvent in the liquid or gas phases (188.8 and 306.7 J/mol·K and 71.03 mL/mol, respectively, for 
DMSO), Vm,gas is the molar volume of the ideal gas at 25 °C (24450 mL/mol), V°m is the molar volume of the solution that 
correspond to the standard conditions (1000 mL/mol). The enthalpies and Gibbs free energies in solution (Hs and Gs, 
respectively) were estimated using the expressions 5 and 6 
Hs = Es(6-311+G*) + Hg(6-31G*) – Eg(6-311+G*)     (5) 
Gs = Hs – TSs           (6) 
where Es and Eg are the total energies in solution and the gas phase and Hg is the gas-phase enthalpy calculated at the 
corresponding level. 
Magnetic shielding was calculated for the equilibrium geometries using the GIAO method70  at the IEFPCM-B3P86/6-
311+G(2d,p)//6-31G(d) level. The 51V chemical shifts were estimated relative to VVOCl3, calculated at the same level of theory. 
The 51V hyperfine coupling constants were estimated at the single-point calculations using the BHandHLYP functional and 6-
311G* basis set for all atoms on the basis of the equilibrium geometry obtained at the B3P86/6-31G*(V-ECP) level of theory. 
The anisotropic 51V hyperfine coupling constants Ax, Ay, and Az were estimated as the sum of the isotropic Fermi contact term 
and corresponding dipolar hyperfine interaction term.71 It must be emphasized that for a VIV-species the hyperfine coupling 
constant (A) values may be negative, but in the literature normally it is their absolute value that is reported. This simplification 
was also adopted in this work. Previously, it was found that half-and-half functionals such as BHandHLYP demonstrate better 
performance in the calculations of EPR parameters than many other hybrid functionals due to more accurate estimates of the 
Fermi contact term.71a-b Atomic charges were calculated using the natural bond orbital (NBO) partitioning scheme. 72 
X-ray crystallography  
Intensity data for and 2 (295 K) were measured on an Agilent Technologies SuperNova Dual CCD with an Atlas detector fitted 
with Mo K radiation ( = 0.71073 Å).  Data processing and absorption corrections were accomplished with CrysAlis PRO.73  
Intensity data for 3 (293 K) were collected on a Bruker AXS-KAPPA APEX II diffractometer fitted with Mo Kα radiation (λ = 
0.71073 Å).  Data processing was carried out with SMART and SAINT,74a and the absorption correction was accomplished with 
SADABS.74b  The structures were solved by direct methods with SHELXS-97 (2)75a and SIR2014 (3),75b and refinement (anisotropic 
displacement parameters (ADP’s) with C-bound H atoms in the riding model approximation and a weighting scheme of the form 
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w = 1/[2(Fo2) + (aP)2 + bP] for P = (Fo2 + 2Fc2)/3) was on F2 by means of SHELXL-2014/7.75c  The N-bound H atoms were refined 
with the distance constraint N–H = 0.88(1) Å.  For 2, disorder was evident in the fluorobenzene ring and this was modeled over 
two positions of equal weight; the dihedral angle between the two orientations is 4(1)°.  Each benzene ring was constrained to 
be an ideal hexagon and, due to the near-overlap of the atoms, equivalent pairs were constrained to have identical ADP’s.  The 
data for 3 was less than optimal but, the structure determined unambiguously without any unusual features.  Crystallographic 
data and final refinement details are given in Table 1.  The molecular structure diagrams were drawn using ORTEP-3 for 
Windows76a at the 35% probability level and the remaining crystallographic figures were drawn with DIAMOND76b using 
arbitrary spheres.  Data manipulation and interpretation were with WinGX76a and PLATON.77  
Table 1 Crystal data and structure refinement details for 2 and 3. 
Compound 2 3 
Formula C14H12FN4O2SV C13H9FN4S 
Formula weight 370.28 272.30 
Color, habit Yellow, prism Orange, prism 
Size mm 0.05 × 0.05 × 0.25 0.10 x 0.12 x 0.20 
Crystal system Monoclinic Monoclinic 
Space group C2/c P21/c 
Unit cell dimensions   
a (Å) 19.600(3) 10.8207(16) 
b (Å) 14.7000(8) 17.650(3) 
c (Å) 14.922(2) 13.3819(19) 
a (º) 90 90 
 (º) 134.83(3) 99.691(5) 
g (º) 90 90 
Volume (Å3) 3049.1(17) 2519.3(7) 
Z/Zꞌ 8/1 8/2 
Calculated density (g cm-3) 1.613 2519.3(7) 
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Radiation Mo K Mo K 
Absorption coefficient (mm-1) 0.812 1.436 
F(000) 1504 1120 
Theta range for data 
collection (º) 
2.7 – 29.4 2.3 – 25.7 
Reflections collected / unique 12030 / 3723 43705 / 4590 
Rint 0.040 0.131 
Data (I>2 (I)) / restraints/ 
parameters 
2197 / 38 / 210 2246 / 2 / 349 
Goodness-of-fit on F2 1.01 1.03 
Final R, wR indices [I>2σ(I)] 0.053, 0.121 0.110, 0.305 
Final R, wR indices [all data] 0.101, 0.149 0.204, 0.385 
a, b wght scheme 0.059, 3.139 0.156, 12.576 
Residual electron density 
   peaks (eÅ-3) 
-0.27, 0.41 -0.47, 0.56 
 
 
 
 
In vitro Glucose uptake assay on L6 myotubes. 
L6 myoblast were cultured in DMEM containing 10% FBS and penicillin (100 U/mL) and streptomycin (100 µg/mL) in a 
humidified 5% CO2 incubator at 37°C. To differentiate to myotubes, the myoblast cells (5x104) were seeded in 24 well plates in 
DMEM containing 2% FBS. The myoblast cells (5x104) were grown for 11 days in 0.4 mL of 2% FBS/DMEM to allow the 
formation of myotubes. The medium was changed every 2 days. On the 11th day, the cells were washed and incubated in Kreb’s 
bicarbonate buffer (KRBB) for 2 h. Myotubes were then further cultured in KRBB containing 25 mM glucose along with 25, 50, 
100 µM of vanadium compounds ([VIVO(L)(acac)] (1), [VVO2(L´)] (2) and VIVO(acac)2) for 4 h, respectively. Insulin (2 µM) was 
taken as positive control.78a The residual glucose in the buffer aliquots remaining in each well after 4 h was estimated using 
hexokiase method by Randox autoanalyser.  
 
Cytotoxicity studies.  
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The effect of complexes 1 and 2 on the MCF–7 cells (a human breast adenocarcinoma cell line) and Vero cells (noncancerous 
mammalian cells) was studied using the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) dye reduction 
assay, by measuring the optical density at 595 nm using a micro plate reader spectrophotometer. The cells were maintained in 
minimal essential medium supplemented with 10% FBS, penicillin-streptomycin solution and incubated at 37°C in 5% CO2 and 
95% humidified incubator. After the cells being grown for 24 h to a subconfluent state (~ 60–70%), they were treated with 
different concentrations of [VIVO(L)(acac)] (1) and [VVO2(L´)] (2) (5, 50, 100, 200 μM) in culture medium. The complexes were 
dissolved in DMSO and working solutions were prepared by diluting the stock of 5 mM of each compound with plain DMEM. 
Final working concentration of DMSO in assay was less than 2%. The samples were tested in triplicates. After 24, 48 and 72 h 
the effect of the compound on cell viability was examined by the MTT test. Optical density was measured at 595 nm using an 
automatic microplate reader.  
DAPI staining.  
DAPI (4´,6-diamidino-2-phenylindole dihydrochloride) staining was carried out to examine the morphology of the nuclei after 
treatment. The cells were grown in the 96–well plates. After reaching approximately 90% confluency the cells were treated 
with [VIVO(L)(acac)] (1) and [VVO2(L´)] (2) at different concentrations (5, 50 100, 200 µM), and were incubated for 24, 48 and 72 
h. Cells were observed with inverted fluorescence microscope after treatment to check for morphological changes, during cell 
death. Then the cells were washed twice with PBS (pH 7.4) and 3.7% of paraformaldehyde was added and incubated for 15 min. 
Then, the cells were again washed twice with PBS and treated with 0.2% triton–X 100 and 2% BSA in PBS for 30 seconds. Again 
the cells were washed twice with PBS and DAPI was added and kept for 30 min in the dark. Finally the cells were washed twice 
with PBS and imaged under fluorescence microscope (FLoiD, Life technologies). 
 
Results and discussion 
Synthesis 
Scheme 1 illustrates the formation of the oxidovanadium(IV) complex, [VIVO(L)(acac)] (1), and the 
dioxidovanadium(V) complexes [VVO2(L´)] (2) and [VVO2(L)] (2a). The spectroscopic data are consistent 
with the proposed formulations. The purity of these compounds was confirmed by elemental analyses. 
All complexes were soluble in EtOH, CH3CN, DMF and DMSO.  
 
Figure 1 deleted 
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Scheme 1 Schematic representation of HL and outline of the processes to obtain [VIVO(L)(acac)] (1), 
[VVO2(L´)] (2) and [VVO2(L)] (2a). 
 
 
The processes take place in two steps: firstly, the formation of [VIVO(L)(acac)] (1) from the reaction of 
[VIVO(acac)2] with HL {4-(p-fluorophenyl)thiosemicarbazone of pyridine-2-aldehyde}. Then, in presence 
of DMSO, there is aerial oxidation of [VIVO(L)(acac)] (1) to form the VVO2-complex [VVO2(L´)] (2), which 
contains a rearranged ligand L´ where methylation of an aldimine carbon has taken place. However, in 
the presence of other solvents such as DMF, CH3CN and EtOH no such ligand change is observed and the 
corresponding VVO2-compound [VVO2(L)] (2a) is formed from [VIVO(L)(acac)] (1). The reaction of 2a with 
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DMSO was also carried out at 60 °C; however, in that case there was no change in colour of the reaction 
mixture or methylation at the aldimine C atom.  
 
 
 
Plausible pathways for the alkylation of complex 1 in the presence of DMSO 
The following pathways A and B can be proposed for the formation of the methylated product [VVO2(L´)] 
(2) from the VIVO-complex [VIVO(L)(acac)] (1). 
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Scheme 2 Possible routes A and B for the alkylation of 1 by DMSO at 60 ⁰C. 
 
 
Pathway A: 
A transient nucleophilic dimsyl species might be formed by the loss of one proton from DMSO as 
depicted in Eq. (i) of Scheme 2. The proton may be taken up by the aldimine N-atom or, in case a 
transient -oxido bridged or hydroxide-VIVOL or VVOL species is formed, the highly basic -oxido or 
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hydroxido ligands may bind the proton. The deprotonation of DMSO by either a V-bonded hydroxide or 
-oxido ligand appears also likely, given that the pKa values of water and DMSO in DMSO are 31.4 and 
35.1.78b-d In fact, DMSO can be deprotonated by bases weaker than dimsyl such as hydroxide or t-
butoxide (pKa of t-butanol: 32.2).78e,f The deprotonation could also be further facilitated by the increased 
acidity of the DMSO C-H bonds upon coordination to the oxophilic VIV or VV moieties. Once formed, the 
dimsyl species attacks the most electrophilic CH moiety nearby (Scheme 2, Eq. ii, A) and forms an 
intermediate species Ia’, which loses CH3SOH species to give rise to another intermediate species Ib. 
Finally, the aerial oxidation of Ib and loss of a Hacac fragment leads to the formation of [VVO2(L´)] (2) (Eq. 
iii; here the source of the proton might be from the DMSO or the moisture present in the DMSO.)  
Pathway B: 
This does not require the formation of a dimsyl anion and involves the direct attack of the carbon atom 
of DMSO to the imine C atom of 1, (Scheme 2, eq. ii, B) with the formation of the intermediate species 
Ia. This intermediate species then forms CH3SOH and Ib, which upon oxidation forms 2 (Eq. iii).  
The proposed pathways are supported by the Natural Bond Orbital (NBO) atomic charge distribution in 
complex 1 (Fig. 2a). Among all CH groups, the carbon undergoing methylation has the highest charge 
together with one of the C atoms of the pyridine ring. There are other C atoms with even higher charges 
but due to steric and electronic constraints we do not expect there methylation. In addition, the NBO 
charges at the C atoms of DMSO are strongly negative, particularly in the dimsyl species (Fig. 2b). 
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Fig. 2 Diagrams depicting NBO atomic charges at the carbon atoms (a) of 1 and (b) of neutral DMSO (left) and the 
dimsyl anion (right).  
 
The structures of intermediates Ia´ and Ia shown in Scheme 2 for pathways A and B were optimized using 
the DFT (B3P86) method. The addition of the dimsyl anion, CH3S(=O)CH2–, to complex 1 giving 
intermediate Ia´ is highly exoergonic (by –35.3 kcal/mol). In turn, structure Ia was found to be 0.3 
kcal/mol more stable than the initial complex 1 plus DMSO (in terms of G in DMSO solution), which is 
quite reasonable for a transient reaction species. The free Gibbs energy of the complete reaction (ii) in 
Scheme 2 (i.e., 1 + DMSO  Ib + CH3SOH) is –20.7 kcal/mol that indicates the thermodynamic feasibility 
of this reaction (either pathway A or B). 
Therefore, both pathways A and B are plausible, the relative importance of A and B depending on the 
temperature, on the pH of the medium and efficacy of basic species (e.g. a -oxido or hydroxide 
vanadium species) in removing a proton from DMSO to yield the CH3S(=O)CH2– anion. 
 
 
 
IR spectroscopy 
The IR spectrum of HL exhibits bands due to ν(N(1)–H) and ν(N(2)–H) moieties in the 3311–2967 cm–1 
region, but complexes 1, 2 and 2a do not exhibit the ν(N(2)–H) band.  This indicates that the ligand 
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coordinates to the metal centre in the anionic form. The sharp band at 836 cm–1, due to ν(C(7)–S(1)) 
stretching in the ligand, is lowered to 775–762 cm–1 in the complexes, indicating participation of the 
thione sulfur in the coordination.78g,h Fig. 3 shows the IR spectra of complexes 1 and 2 in the 1100-800 
cm1 range. The presence of a strong sharp band at 949 cm–1 in 1 suggests the presence of oxido 
(V=O)79, whereas two peaks in the range 937–922 cm–1 in 2 and 2a are assigned to dioxido (V=O) 
stretchings.80  The IR data are summarized in Table 2. 
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Fig. 3 FTIR spectra of (a) [VIVO(L)(acac)] (1) and (b) [VVO2(L´)] (2) showing the (V=O) stretching bands. 
 
 
Table 2 IR and electronic spectral data for complexes 1, 2 and 2a.  
Complex V−O str,a cm-1 UV−Visb λmax, nm (, dm3mol-1cm-1) 
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[VIVO(L)(acac)] (1) 949  272 (20703), 332 (25043), 401 (21818), 444  (18182), 
603 (120), 761  (45) 
[VVO2(L´)] (2) 937, 925 <257 (24048), 431 (19919) 
[VVO2(L)] (2a) 934, 922 260 (26127), 428 (19919) 
aIn KBr pellet. bSolutions in CH3OH.  
 
UV−Vis spectroscopy 
The electronic spectra of 1, 2 and 2a were recorded in CH3OH solution and part of the spectra of 
complexes 1 and 2 are depicted in Fig. 4. In all complexes two strong absorption bands are observed in 
the wavelength range 431–257 nm. The lower energy absorptions at 430-400 nm are ascribable to 
ligand to metal charge transfer (LMCT) transitions,80a whereas the higher energy absorptions are likely to 
be due to ligand centred transitions.80b Two weak absorptions at 761 nm (max = 45 dm3mol1cm1) and 
603 nm (max = 120 dm3mol1cm1) observed for 1 (a VIV complex) are assigned to d−d transitions. 79-81a 
The UV−Vis data are summarized in Table 2.  
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Fig. 4 Part of the electronic absorption spectra of methanolic solutions of (a) [VIVO(L)(acac)] (1.8104 M) 
(1) and (b) [VVO2(L´)] (2) (1.5105 M).  
EPR spectroscopy 
The EPR spectrum of 1 was measured in frozen solution of DMF at 77 K (Fig. 5). The experimental spin 
Hamiltonian parameters obtained are: gx,y =1.978, gz=1.952, |Ax,y| = 51.9×104 cm1, |Az| = 153.2×104 
cm1. The obtained z-component spin Hamiltonian parameters are consistent with a [Nim, Npy, Oacac, SRS] 
equatorial donor atom set.79,81b-d The |Az| value calculated by DFT procedures (see above), after the 
structural optimization of complex 1, is 154.610–4 cm–1, reasonably correlating with the experimental 
value. 
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Fig. 5 First derivative of the X-Band EPR spectrum of 1 in DMF (0.0025 M) recorded at 77 K.  
NMR spectroscopy 
The 1H NMR spectrum of HL (Fig. S3) was recorded in DMSO-d6. It exhibits two singlets in the range 
12.08 to 10.29 ppm due to two NH moieties {N(1)H and N(2)H}, whereas in the spectra of complexes 2 
and 2a (Figs. S4 and S5) there is only one peak in the range 10.29 to 10.20 ppm for one NH moiety 
{N(1)H}, indicating coordination of the ligand to the metal centre in anionic form. The peak due to C(8)H 
appears as a singlet at 8.59 ppm for the ligand and at 8.79 ppm for 2a. The presence of a methyl peak at 
2.66 ppm in the spectrum of [VVO2(L´)] (2) and absence of a C(8)H peak indicates the methylation at 
imine carbon C(8) and formation of a new ligand. The detailed NMR data is included in the experimental 
section. 
The reaction of HL with DMSO in the absence and presence of VIVOSO4 or VVO(OiPr)3 was tested further 
with distinct conditions of temperature and period of reaction, this being monitored by 1H NMR 
experiments (Figs. S6−S11). No alkylation reaction is noticeable since the CH=N resonance at ca. 8.75 
ppm did not subside. These results reinforce the assessment that the methylation reaction may be 
confined to complex 1. 
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Moreover, the reaction of complex 1 with DMSO at 60⁰C was monitored by 1H and 51V NMR. A saturated 
solution of 1 in DMSO was heated to 60⁰C till all solid dissolved (ca. 10 minutes). A gradual colour 
change from green to brown was observed. The solution rested at room temperature for another 2 h 
before NMR analysis. It was observed that the CH=N resonance at δ 8.75 ppm nearly disappeared (Figs. 
6 and S12).  
 
Fig. 6 Low field region of the 1H NMR spectrum of 1 (ca. 0.19 M) in DMSO after heating for 10 min at 60⁰C 
and cooling down for 2 h to room temperature. The resonance at 8.75 ppm is assigned to the imine 
proton (CH=N).  
 
The respective 51V NMR spectrum (Figs. 7 and S13) shows two broad but faint resonances at ca. δV = -
434 ppm and δV = -577 ppm. There are still some VIVO-species in solution and the resonances are 
tentatively assigned to a VVO2-species and a µ-oxido bridged VVO-species, respectively. The chemical 
shift δV calculated by DFT (δVcalc) for 2a is -433 ppm, thus supporting the assignment of the experimental 
resonance at -434 ppm; for complex 2 the δVcalc is -449 ppm. The above observations indicate that the 
reaction proceeds swiftly at 60 ⁰C. 
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Fig. 7 Close-up of the 51V NMR spectrum of 1 (ca. 0.19 M) in DMSO after heating for 10 min at 60⁰C and 
cooling down for 2 h to room temperature.  
 
The reaction of compound 2a with DMSO at 60 ºC was also monitored by 1H and 51V NMR using the 
same procedure as for 1. In this case there was no change in color or apparent alteration of the 1H NMR 
spectrum after 24 h: the CH=N resonance at  8.75 ppm remained present with an integration indicative 
of 1 proton (Fig. S14). Other experiments showed that no alteration occurred after 24 h at 60 ºC in 
DMSO (Fig. S14, B). Only after 5 days under these conditions the CH=N resonance disappeared, but the 
obtained end product revealed to be a cyclized and oxidized compound 3 (Figs. S1 and S15, see Table S1 
for selected bond lengths and angles). The driving force for this intramolecular cyclisation comes from 
the highly nucleophilic character of the thiolate moiety. Upon dissociation from the vanadium center, 
the thiolate attacks the electrophilic imine carbon, forming a cyclic thioaminal. The aromatisation of this 
heterocycle to a nitrogenated thiophene favors the subsequent oxidation step, most likely by 
vanadate(V) formed upon solvolysis of the complex. 
The 51V NMR spectrum obtained from the experiments at 24 h showed only one broad but faint 
resonance at ca. V = -434 ppm, which may be assigned to the cis-VO2 species 2a. Species at higher field, 
specifically at V -530 ppm, only appeared after 5 days at 60 ⁰C, but by then decomposition of the 
complex had already occurred. It may be due to an inorganic vanadate species soluble in DMSO, but 
considering that the ligand undergoes significant transformations it may also be a not characterized and 
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unknown VV-species. These experiments indicate that the cis-dioxidovanadium(V) complex 2a is unable 
to mediate the intramolecular methylation of the ligand with DMSO. 
 
NMR spectra upon methylation attempts of other imine ligands 
To test the scope of applicability of methylation reactions in DMSO, several other –C=N containing 
compounds (L1-L10) (Chart 1), along with some VIVO complex (for example C1, Chart 1), were subjected 
to the same conditions as those used for 1. Compounds L1-L10 were prepared in situ by mixing 
equimolar amounts of an aldehyde or ketone and amine in DMSO. After 5 min of stirring at room 
temperature, an equimolar amount of VIVO(acac)2 or VVO(OiPr)3 was added to the reaction mixture. 
After complete dissolution of the metal precursor the mixture was heated to 60 ⁰C in DMSO for 30 min 
to 1 h, depending on the ligand precursor used. The 1H NMR spectra of the obtained solutions were 
measured and compared, when possible, to those obtained for the expected ketimine products (Figs. 
S16−S22). Somewhat broadened 1H NMR spectra were obtained in most cases even when a VV precursor 
was used. This is due to the significant presence of paramagnetic VIV-species, which in the case of the VV 
precursors, could have been formed by the oxidation of the in situ ligand. In some instances, such as 
when L4 and L5 were used, significant precipitation of solids precluded the measurement of adequate 
NMR spectra. Notwithstanding, despite the broadened spectra obtained in most cases, no alkylation 
could be detected with any of the compounds L1-L10 and complexes tested. Importantly, the ligand HL 
was not alkylated when the metal precursor was VVO(OiPr)3 (Fig. 8). Therefore, these results indicate 
that the alkylation reaction is confined to the specific case of 1 and, for this system in particular, a VIVO-
species appears to be a requisite for the reaction to occur.  
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C1 L1 L2 L3 
 
 
 
 
L4 L5 L6 L7 
 
 
 
 
L8 L9 L10  
 
Chart 1 Structural formulas of the ligands and VIVO complex tested in attempts for the alkylation 
reaction with DMSO. Compound C1 was prepared as reported in the literature. 81e The L ligand in C1 
refers to a coordinated solvent molecule, in this case, DMSO or water.  
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Fig. 8 (A) 1H NMR spectra of a 1:1 mixture of HL and VVO(OiPr)3 in DMSO after 10 min. at 60⁰C; (B) 1:1 
mixture of HL and VVO(OiPr)3 in DMSO after 30 min. at 60⁰C; (C) 1:1: mixture of HL, VVO(OiPr)3 and H2O 
in DMSO after 10 min. at 60⁰C; (D) 1:1: mixture of HL, VVO(OiPr)3 and H2O in DMSO after 30 min. at 60⁰C. 
No alkylation of HL may be detected from the analysis of these spectra. Reagent concentration was ca. 
90 mM. 
 
ESI-MS studies 
The negative and positive ESI-MS spectra obtained for compound 1 (Figs. 9 and 10) are of great 
complexity due to aggregation, but the major peaks were identified. The sample was diluted in 
methanol in an attempt to minimise aggregation. The ESI-MS spectrum in the negative mode shows two 
identifiable major species at m/z = 355 and 385 which are assigned respectively to the free methylated 
ligand (HMeL) [(MeL)·2H2O·MeOH] (m/z= 355) and the complex {[VIVO(MeL)]OMe}(m/z=385). As for 
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the positive mode ESI-MS spectrum, three major peaks were identified: (1) the peak at m/z = 242 is 
assigned to {[VIVO(HMeL)]·4MeOH}2+ (m/z= 483/2 = 241.5), whereas (2) the peak at m/z = 321 is 
assigned to [(H2MeL)·MeOH]+, and (3) the peak at m/z = 778 is tentatively assigned to a mixed valence -
oxido bridged species, {Na[VVO(MeL)OMe]-O[VIVO(MeL)]}+. Lower mass peaks are present in both 
positive and negative spectra, which are indicative of fragmentation. In the positive mode the weak 
peak at 439.97 could be assigned to the molecular ion 1·H+. Despite the complexity of the obtained MS 
spectra, these clearly show that a reaction between 1 and DMSO took place with the formation of 
methylated products. 
 
Fig. 9 Negative mode ESI-MS spectrum of 1 in DMSO after 10 min at 60 ºC and ca. 2 h at room 
temperature. The sample was diluted in methanol. 
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Fig. 10 Positive mode ESI-MS spectrum of 1 in DMSO after 10 min at 60⁰C and ca. 2 h at room 
temperature. The sample was diluted in methanol.  
 
Electrochemical properties 
The electrochemical properties of 1 and 2 were examined in CH3CN solution (0.1 M TEAP) by cyclic 
voltammetry using a platinum working electrode, platinum auxiliary electrode, and Ag/AgCl reference 
electrode. The potential data are listed in Table 3. The voltammogram pattern for 1 includes both 
oxidation and reduction processes (Fig. 11(a)); the redox couple at E1/2 value 0.62 V corresponds to 
VIV/VV oxidation, whereas E1/2 at –1.13 V corresponds to VIV/VIII reduction couple. The voltammogram 
pattern for 2 includes only a quasi-reversible redox couple at E1/2 = –0.73 V corresponding to VV/VIV 
reduction (Fig. 11(b)). The redox characteristics of 2a were also examined by measuring the 
corresponding voltammogram; as expected this is very similar to that of complex 2.  
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Fig. 11 Cyclic voltammograms of [VIVO(L)(acac)] (1) (a) and [VVO2(L´)] (2) (b) in CH3CN solution. 
 
Table 3 Cyclic voltammetric[a] data for [VIVO(L)(acac)] (1) and [VVO2(L´)] (2) at 298 K. 
Complex    VIV/VV                                     VIV/VIII                                    VV/VIV 
    Ea1/2(ΔEaP)                            Ec1/2(ΔEcP)                   Ec1/2(ΔEcP) 
[VIVO(L)(acac)] (1)     0.62(450)     –1.13(200)   – 
[VVO2(L´)] (2)         –     –  –0.73(120) 
[a]In CH3CN at a scan rate 100 mV/s. E1/2 = (Epa + Epc)/2, where Epa and Epc are anodic and cathodic peak 
potentials vs. Ag/AgCl, respectively. ΔEP = Epa – Epc. 
 
 
X-ray diffraction crystallography.  
Text deleted  
It was not possible to obtain X-ray diffraction quality crystals of 1 but, there are two closely related 
structures in the literature. These feature very similar atom donor sets, geometries and with oxido and 
acac ligands as in 1 but, with 2-acetylpyridine-4-phenylthiosemicarbazato82 and 
dimethylthiosemicarbazonato83 as the tridentate ligands. 
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A view of the molecular structure of 2 is shown in Fig. 12 and selected geometric parameters are 
collected in Table 4.  In this structure, the V(V) atom is bonded to the S, N, N-donors of the uninegative 
tridentate ligand, as for 1, and two oxido-O atoms.  The length of the C–S bond [1.730(3) Å] is suggestive 
that the ligand is coordinating as a thiolate, a conclusion also supported by the short C7–N2 [1.305(4) Å] 
and C8–N3 [1.306(4)] bonds.  By contrast to 1, the V1,S1,N2,N3,C7 and V,N3,N4,C8,C10 five-membered 
chelate rings are each planar, having r.m.s. deviations of 0.018 and 0.015 Å, respectively, and form a 
dihedral angle of 2.6(1)°.  The pyridyl ring forms dihedral angles of 4.26(17) and 4.0(5)° with the adjacent 
chelate ring and terminal fluorophenyl ring, respectively, indicating that the entire tridentate ligand is 
approximately planar.  The N2O2S donor set defines a highly distorted coordination geometry as seen in 
the value of the trigonality index,   = 0.43, which is intermediate between square pyramidal ( = 0.0) 
and trigonal bipyamdial ( = 1.0).84 Reflecting the higher oxidation state and lower coordination number, 
the V–S bond length in 2 is shorter than the equivalent bond in 1.  To a first approximation, the observed 
molecular structure of 2 matches that reported for the N-bound methyl derivative which differs in 
geometric parameters.  In the latter the V–S [2.3759(9) Å], V–O [1.631(2) Å] and N3–C8 [1.323(4) Å] 
bond lengths are marginally longer than in 2;85  the coordination geometry is closer to square pyramidal 
( = 0.22).  
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Fig. 12 Ortep representation (35%) showing a view of the molecular structure of 2; one of the disorder 
components of the fluorophenyl ring was omitted for reasons of clarity. 
 
Table 4 Selected geometric parameters (Å , °) for 2 
Atoms Parameter Atoms Parameter 
Complex 2    
V–S1 2.3653(13) V–O1 1.607(2) 
V–O2 1.596(3) V–N3 2.143(3) 
V–N4 2.086(3) C7–S1 1.730(3) 
C7–N2 1.305(4) N2–N3 1.374(4) 
C8–N3 1.306(4)   
S1–V–O1 101.93(10) S1–V–O2 98.93(11) 
S1–V–N4 77.58(7) S1–V–N4 151.34(10) 
O1–V–O2 110.14(16)   
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Fig. 13 Ortep representation (35%) showing a view of the molecular structure of 3, first independent 
molecule. 
Two independent molecules comprise the asymmetric unit of 3, Figs. 13 and S23a, and these adopt very 
similar conformations as seen in the overlay diagram in Fig. S23b.  The structure features a 1,3,4-
thiadiazolyl ring with 4-fluorophenylamine and 2-pyridyl substituents at the 2- and 5-positions.  The five-
membered ring is strictly planar (r.m.s. deviation = 0.002 Å) and this forms dihedral angles of 13.1(4) and 
1.5(3)° with the 4-fluorophenylamine and pyridyl substituents, respectively, reflecting a small twist 
about the N1–C8 bond as seen in the value of the C1–N1–C8–C9 torsion angle of 11.4(16)°; the dihedral 
angle between the outer substituents is 12.6(5)°.  The second independent molecule is considerably 
more planar with the dihedral angles between the 1,3,4-thiadiazolyl ring and 4-fluorophenylamine and 
2-pyridyl groups being 2.5(5) and 0.8(4)°.  In each molecule, the pyridyl-N4 atom is orientated to be 
proximate to the ring-S1 atom with the S1…N4 separation of 2.945(8) Å (2.953(8) Å for the second 
molecule) suggestive of attractive contacts86 consistent with the observed planar relationship between 
the 1,3,4-thiadiazolyl and pyridyl rings.  The molecular packing of the complexes has been discussed in 
detail in the ESI section (Figs. S24-S27). 
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In vitro insulin mimetic activity. The in vitro insulin mimetic activity of the 1 and 2 was tested against 
insulin responsive L6 myoblast cells and the results have been included in the ESI section (Fig. S28). 
Cytotoxicity Studies. In the present work in vitro cytotoxicity studies of complexes 1 and 2 was assayed 
by determining the viability of MCF–7 (breast cancer cells) and Vero cells (noncancerous mammalian 
cells) using the MTT assay. The ligand HL and VIVO(acac)2 gave high IC50 values at 24 h higher than 200 
μM, whereas [VIVO(L)(acac)] (1) and [VVO2(L´)] (2) gave lower IC50 values that are depicted in Table 5. It 
was observed that, upon increase in time of incubation from 24 to 72 h, the IC50 values decrease, being 
lower for the Vero cells, but they do not differ much for 48 and 72 h. In comparison to the IC50 values 
obtained, cisplatin a well-established chemotherapeutic drug, has an IC50 value of 286 μM at 72 h.87 
The cytotoxicity of some VIVO-complexes of salicylaldimines and polypyridyl ligands, here designated as 
[VIVO(sal-AMA)(NN)] were recently also studied against MCF-7 cells,87 where the IC50 values varied 
between 5.9 ± 1.4 to 40.9 ± 7.5 μM at 24 h and between 2.8 ± 1.3 to 8.4 ± 2.4 μM at 72 h. The present 
compounds depict comparable IC50 values at 24 h to those of this previous report, but with somewhat 
higher IC50 values; thus complexes 1 and 2 are less toxic against MCF-7 cells than the tested [VIVO(sal-
AMA)(NN)] compounds,87 probably due to the presence of the polypyridyl ligands in the latter group of 
complexes.  
Table 5 IC50 (µM) values in MCF–7 and Vero cell lines for complexes 1 and 2 
Cell Line  Time / h IC50 values (µM) 
   1 2 
     
MCF-7  24 28.49 0.45 115.621.02 
48 26.34 0.36 90.610.97 
72 23.15 0.38 84.040.93 
   
Vero cells  24 41.57 0.54 120.55 1.12 
48 3.100.25 30.06 0.31 
72 3.200.28 29.420.38 
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The higher IC50 values of HL (and of VIVO(acac)2) in comparison to the metal complexes 1 and 2 indicate 
that the incorporation of vanadium in the ligand environment increases the cytotoxicity towards these 
cells. It is plausible that the permeation of the vanadium complexes through the lipid layer of the cell 
membrane is favoured by coordination, the polarity of the ligand and the central metal ion being 
globally decreased through charge equilibration.88,89a Bovine serum albumin (BSA) is present in relatively 
high concentration in FBS, which was added in 10% to the incubation medium. Albumins, e.g. BSA may 
serve as vehicles of uptake of drugs, namely metal-based drugs89b by the cells, thus it is also possible 
that the higher toxicity of 1 and 2 when compared to the ligand, might be due to distinct binding to the 
albumin leading to a more efficient uptake in the case of complexes 1 and 2. Similarly with VIVO(acac)2 
which binds albumins rather weakly.89c  
It may be concluded from the present in vitro data that the metal complexes exhibit greater biological 
activities than the free ligands, which is also in accordance with previous reports.87,90  Apart from the 
possible higher uptake of complexes when compared with the corresponding ligands, or synergistic 
effects operating, vanadium ions by themselves present some toxicity.91  Comparing the activity of the 
two complexes, it is observed that the toxicity of [VIVO(L)(acac)] (1) is greater than that of [VVO2(L´)] (2), 
which is reflected from their IC50 values with dose dependency illustrated in Figs. 14 and 15 and Table 5, 
which can either be correlated with the difference in the oxidation states of the complexes or to 
different uptake efficiency by the cells.  
 
 
 
 
 
 
 33 
 
 
 
 
Fig. 14 Effect of [VIVO(L)(acac)] (1) on cell viability and growth: MCF–7 and Vero cells were treated with 
different concentrations of the test compound for 24 h, 48 h and 72 h and then cell viability was 
measured by the MTT assay. Data reported as the mean ± S.D. for n = 3 and compared against control 
(considered as 100% viability).  
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Fig. 15 Effect of [VVO2(L´)] (2) on cell viability and growth: MCF-7 and Vero cells were treated with 
different concentrations of the test compound for 24 h, 48 h and 72 h and then cell viability was 
measured by the MTT assay. Data reported as the mean ± S.D. for n = 3 and compared against control 
(considered as 100% viability).  
 
Nuclear staining assay. Aspects of the mechanism of cell death due to the complexes (1 and 2) were 
checked by staining dying cells with DAPI. The density of the DAPI stained nuclei was used to check the 
dead cells or those that have compromised membranes in different treatment groups. Fig. 16 shows 
images taken after DAPI staining in blue fluorescence at different concentrations of the complexes. It 
can be seen from the figure that the number of DAPI stained nuclei were reduced in treated wells with 
increasing concentrations of the complexes indicating the dose dependent cell death. Fig. 17 shows the 
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grey scale images at different time points after the treatment with minimum toxic concentrations of the 
complexes (5 µM). The distinct nuclear condensation and fragmentation was seen in treated cells 
compared to control cells. Upon increase in time of incubation (from 24−72 h), the treated cells 
exhibited a shrinking morphology which indicated that, with increase in time, apoptosis of the cells took 
place. The changes with increasing of incubation time were more drastic for complex 2 which is 
significantly more cytotoxic than complex 1.  
(a) [VIVO(L)(acac)] (1) 
 
         
(b) [VVO2(L´)] (2) 
 
         
 
Fig. 16 Changes of MCF-7 cells observed by fluorescence microscopy upon staining with DAPI (see 
experimental) after 24 h incubation. Images B–E clearly show the decrease in the number of live cells 
with increasing concentration of the drugs (compared to the control, A). 
 
A: control B: 5 M C: 50 M D: 100 M E: 200 M 
A: control B: 5 M C: 50 M D: 100 M E: 200 M 
 36 
(a) [VIVO(L)(acac)] (1): 
 
 
 
 
 
(b) [VVO2(L´)] (2): 
  
                          
 
Fig. 17 (a and b) Changes of MCF-7 cells observed by fluorescence microscopy upon staining with DAPI: 
F-I show changes in nuclei with respect to the treatment time. Arrows show the morphological changes 
in nuclei of MCF-7 cells observed on applying 5 µM vanadium complexes (1 and 2) in comparison to 
control.  
 
 
 
 
 
 
F: control G: 24 h H: 48 h I: 72 h 
F: control G: 24 h H: 48 h I: 72 h 
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Conclusions 
The syntheses and characterization of the VIVO-complex [VIVO(L)(acac)] (1) and of two VVO2-complexes 
[VVO2(L')] (2) and [VVO2(L)] (2a), prepared with the Schiff based derived from 4-(p-fluorophenyl) 
thiosemicarbazone and pyridine-2-aldehyde (HL) is achieved. The synthesized HL and the metal 
complexes were characterized by elemental analysis, IR, UV–Vis, NMR/EPR spectroscopy and ESI-MS. 
Keeping 2a dissolved in DMSO at ca. 60 ºC, within a few hours the thiolate attacks the electrophilic 
imine carbon, forming a cyclic thioaminal; after 5 days a cyclized and oxidised compound 3 was isolated 
and characterized by single-crystal x-ray diffraction.  
The molecular structure of complex 2 was determined by single crystal X-ray crystallography. Complex 
[VIVO(L)(acac)] (1) is found to undergo methylation at the aldimine carbon of the ligand in the presence 
of DMSO forming the VVO2-species [VVO2(L')] (2). A nucleophilic dimsyl species (CH3SOCH2–), generated 
from DMSO, or direct attack of the CH3SOCH3 carbon to the aldimine carbon, while recrystallization is 
taking place, is probably responsible for the methylation reaction. Attempts to carry out similar 
methylation with various other ligands and complexes prepared from different vanadium precursors 
under similar reaction conditions were followed by 1H NMR and it was found that no such methylation 
occurred in any of these systems. Moreover, when the dioxidovanadium(V) complex 2a , or the ligand L 
in the presence of VVO(OiPr)3, dissolved in DMSO, were subjected to heating at 60 °C, no transformation 
to the methylated product took place. Hence, it can be concluded that the methylation of the aldimine 
carbon by DMSO is ligand specific and takes place only when vanadium is in VIVO state.  
Complexes 1 and 2 show in vitro insulin mimetic activity against insulin responsive L6 myoblast cells, 
with complex 1 being more active. In addition, the in vitro cytotoxicity studies of complexes 1 and 2 
against the MCF–7 and Vero cell lines were also assayed, but the compounds are not very toxic, 
depicting IC50 values (M) at 48 h against MCF-7 cells of ~26.3 (1) and ~90.6 (2), and against Vero cells 
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IC50 values (M) at 48 h of ~3.1 (1) and ~30.1 (2). DAPI staining experiments were done to disclose the 
effect of the complexes on the morphology of the cells, the results indicating that increase in time of 
incubation as well as increase of concentration of the complexes lead to increase in cell death. 
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